source
- FDA advisory panel advises against approving Capricor’s Duchenne cell therapy, deramiocelThe FDA Cellular, Tissue, and Gene Therapies Advisory Committee convened to evaluate deramiocel, a cell‑based treatment for Duchenne muscular dystrophy developed by Capricor Therapeutics. Capricor…
- Caldera Therapeutics completes reverse merger with Synlogic, secures $278 million financingCaldera Therapeutics, a Massachusetts biotech founded last year, announced a reverse merger with Nasdaq-listed Synlogic, giving it a public listing. The transaction includes a $278 million financi…